A NOVEL FRAMEWORK TO ESTIMATE MULTIDIMENSIONAL MINIMUM EFFECTIVE DOSES USING ASYMMETRIC POSTERIOR GAIN AND ε-TAPERING
成果类型:
Article
署名作者:
Cheung, Ying Kuen; Chandereng, Thevaa; Diaz, Keith M.
署名单位:
Columbia University; Columbia University
刊物名称:
ANNALS OF APPLIED STATISTICS
ISSN/ISSBN:
1932-6157
DOI:
10.1214/21-AOAS1549
发表日期:
2022
页码:
1445-1458
关键词:
phase-i trials
sedentary behavior
clinical-trials
older-adults
DESIGN
combination
mortality
toxicity
patterns
time
摘要:
In this article we address the problem of estimating minimum effective doses in dose-finding clinical trials of multidimensional treatment. We are motivated by a behavioral intervention trial where we introduce sedentary breaks to subjects with a goal to reduce their glucose level monitored over 8 hours. Each sedentary break regimen is defined by two elements: break frequency and break duration. The trial aims to identify minimum combinations of frequency and duration that shift mean glucose, that is, the minimum effective dose (MED) combinations. The means of glucose reduction associated with the dose combinations are only partially ordered. To circumvent constrained estimation due to partial ordering, we propose estimating the MED by maximizing a weighted product of combinationwise posterior gains. The estimation adopts an asymmetric gain function, indexed by a decision parameter epsilon, which defines the relative gains of a true negative decision and a true positive decision. We also introduce an adaptive epsilon-tapering algorithm to be used in conjunction with the estimation method. Simulation studies show that using asymmetric gain with a carefully chosen epsilon is critical to keeping false discoveries low, while epsilon-tapering adds to the probability of identifying truly effective doses (i.e., true positives). Under an ensemble of scenarios for the sedentary break study, epsilon-tapering yields consistently high true positive rates across scenarios and achieves about 90% true positive rate, compared to 68% by a nonadaptive design with comparable false discovery rate.